in vitro News and Research

RSS

Study: Flavoring chemicals of e-cigarette vapor alone can measurably damage the lungs

Known for their appetizing flavors, such as bubblegum, banana and strawberry, e-cigarettes continue to grow in popularity around the world. Promoted by makers as a "healthy" alternative to regular tobacco cigarettes, researchers are finding e-cigarettes, or vaping, still result in injury to the lungs.

15 Dec 2020

World Health Organization issues notice for in vitro diagnostics users

Nucleic acid testing (NAT) technologies that use real-time polymerase chain reaction (RT-PCR) for detection of SARS-CoV-2.

14 Dec 2020

Recovered COVID-19 patients exhibit persistent cellular immunity

Researchers at The Rockefeller University in New York have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – triggers persistent T cell responses that last for at least six months.

14 Dec 2020

SARS-CoV-2 Nsp3 protease activity and nanobody inhibitor development

A new study published in the pre-print server bioRxiv* explores the viral enzyme PLpro, encoded in the nonstructural protein nsp3, and its inhibitors. T

14 Dec 2020

Researchers develop first biohybrid artificial retina with silk fibroin and retinal cells

An international research led by the Complutense University of Madrid has taken a further step to solve the age-related macular degeneration (AMD)-derived blidness problem with the development of the first biohybrid artificial retina built with silk fibroin and retinal cells.

11 Dec 2020

Research provides new insights into Glioblastoma invasiveness

One of the hallmarks of Glioblastoma (GBM), the most aggressive type of brain cancer, is its high invasive capacity, which leads to its expansion into the normal brain tissue.

11 Dec 2020

UCLA researchers identify gene that could help predict cervical cancer treatment response

UCLA researchers have identified a potential diagnostic marker that could help predict how likely someone with cervical cancer is to respond to the standard treatment of chemotherapy and radiation.

11 Dec 2020

Researchers use AI platform to identify best combination of available therapies against COVID-19.

A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

11 Dec 2020

Using AI to find optimal combination of available therapies against SARS-CoV-2

A team of researchers from the National University of Singapore has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

10 Dec 2020

Antiepileptic drug reduces early signs of clinical dysfunction in people with ALS

The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital.

10 Dec 2020

Hydroxychloroquine found ineffective as post-exposure SARS-CoV-2 prophylaxis

Now, a study on the utility of hydroxychloroquine as prophylaxis against COVID-19, has been released in the latest issue of Annals of Internal Medicine.

10 Dec 2020

Reverse phenotyping shows reactive T cell profiles in SARS-CoV-2 infection

A new study appearing as a preprint on the medRxiv* browser in December 2020 employs reverse phenotyping technology to explore T cell responses in COVID-19.

10 Dec 2020

Pioneering diagnostics platform changes the way COVID-19 is detected

Montreal-based Two-Photon Research Inc. announces CAST, a diagnostics platform that changes the way viruses are detected. The CAST platform uses TPR’s patented Aptamer Molecular Photonic Beacon™ that photonically interfaces with smartphones.

10 Dec 2020

EKF launches high performance quantitative COVID-SeroKlir antibody test kit

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.

From EKF Diagnostics 10 Dec 2020

New consortium aims to understand principles underlying the formation of coronaviruses

The University of California, Riverside, is the recipient of a 2021 UC Multicampus Research Programs and Initiatives, or MRPI, award allowing the campus to put together a UC Coronavirus Assembly Research Consortium.

9 Dec 2020

The effects of cigarette smoke and COPD on SARS-CoV-2 infection

Researchers have revealed some of the effects of cigarette smoke and chronic obstructive pulmonary disease (COPD) on SARS-CoV-2 infection.

9 Dec 2020

Neutrophils may play a key role in COVID-19-related thrombosis

A team of researchers in Italy have published a study suggesting that rather than platelets, neutrophils could be playing the lead role in thrombotic complications associated with COVID-19.

9 Dec 2020

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

Bioactive tea compounds show potential anti-SARS-CoV-2 activity

Scientists have revealed that certain bioactive compounds found in green, black, and oolong tea possess remarkable antiviral activities against SARS-CoV-2.

8 Dec 2020

UCI researchers develop new technology to rapidly hypermutate antibodies

Using the same strain of yeast that ferments wine and makes dough rise, a team led by University of California, Irvine and Harvard Medical School researchers has developed an in vitro technology that can rapidly hypermutate antibodies.

8 Dec 2020